BARDA and Locus in tie-up to tackle UTIs with phages

BARDA and Locus in tie-up to tackle UTIs with phages

Source: 
Biopharma Reporter
snippet: 

Locus Biosciences has signed a contract with BARDA to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage) that targets E. coli bacteria causing recurrent urinary tract infections (UTIs).